PPP3CC: A Potential Drug Target and Biomarker for Calcineurin A Subunit Gamma Isoform

Target Name: PPP3CC

NCBI ID: G5533

PPP3CC

Other Name(s): Calmodulin-dependent calcineurin A subunit gamma isoform | protein phosphatase 3, catalytic subunit, gamma isozyme | CNA3 | Protein phosphatase 2B, catalytic subunit, gamma isoform | protein phosphatase 3 catalytic subunit gamma | PPP3CC variant 2 | PP2BC_HUMAN | Protein phosphatase 3 catalytic subunit gamma, transcript variant 2 | Calcineurin, testis-specific catalytic subunit | Protein phosphatase 3 (formerly 2B), catalytic subunit, gamma isoform | CALNA3 | calcineurin, testis-specific catalytic subunit | CAM-PRP catalytic subunit | PP2Bgamma | Serine/threonine-protein phosphatase 2B catalytic subunit gamma isoform (isoform 2) | Serine/threonine-protein phosphatase 2B catalytic subunit gamma isoform | Calcineurin (PP-2B, PP-3)

PPP3CC: A Potential Drug Target and Biomarker for Calcineurin A Subunit Gamma Isoform

Calcineurin A subunit gamma isoform, also known as PPP3CC (calmodulin-dependent calcineurin A subunit gamma), is a protein that plays a crucial role in regulation of cellular signaling pathways, including intracellular signaling, protein-protein interactions, and intracellular signaling by protein kinases. The dysregulation of PPP3CC has been implicated in various diseases, including neurodegenerative disorders, cancer, and inflammation. Therefore, targeting this protein provides new insights into the pathogenesis of these diseases and may lead to the development of new therapeutic strategies.

Drugs that target PPP3CC have the potential to modulate its activity and improve therapeutic outcomes. Several small molecules and biochemicals have been shown to interact with PPP3CC, and some of these compounds have been tested in animal models of neurodegenerative disorders. However, the exact mechanism of action and their efficacy in clinical trials are not well understood.

Importance of PPP3CC as a drug target

PPP3CC is a protein that is expressed in various tissues and cell types, including neurons, muscle cells, and immune cells. It is a key regulator of intracellular signaling pathways, including the cAMP/cGMP signaling pathway, which is involved in various cellular processes, including cell signaling, protein-protein interactions, and intracellular signaling by protein kinases. The dysregulation of PPP3CC has been implicated in the development and progression of various neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

In addition to its role in neurodegenerative disorders, PPP3CC is also a potential drug target for other diseases. For example, the dysregulation of PPP3CC has been implicated in the development and progression of cancer, including breast cancer and lung cancer. Therefore, targeting PPP3CC may provide new insights into the pathogenesis of these diseases and lead to the development of new therapeutic strategies.

Conclusion

In conclusion, PPP3CC is a protein that plays a crucial role in regulation of cellular signaling pathways and its dysregulation has been implicated in the development and progression of various neurodegenerative disorders and cancer. The development of new therapeutic strategies that target PPP3CC may provide new insights into the pathogenesis of these diseases and lead to the development of new treatments. Further research is needed to fully understand the mechanism of action of PPP3CC and to explore its potential as a drug target.

Protein Name: Protein Phosphatase 3 Catalytic Subunit Gamma

Functions: Calcium-dependent, calmodulin-stimulated protein phosphatase which plays an essential role in the transduction of intracellular Ca(2+)-mediated signals. Dephosphorylates and activates transcription factor NFATC1. Dephosphorylates and inactivates transcription factor ELK1. Dephosphorylates DARPP32

The "PPP3CC Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PPP3CC comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets